Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna said on Monday its experimental influenza vaccine was found to be 26.6% more effective than a currently approved annual flu shot when tested in adults aged 50 years and older in a late-stage ...

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of selling combination vaccines.

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older ...

in a Phase 1/2 clinical trial, Moderna’s combination vaccine appeared to elicit “strong” immune responses against both influenza and Covid-19 and was found to be safe the company announced ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the company pulled its application for a combo flu/COVID-19 shot, saying it would ...

Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for FDA approval and 2026 rollout.

Moderna said Monday that its combination vaccine against flu and COVID-19 drew a greater immune response in late-stage study results than two comparable vaccines on the market.

Moderna Inc. says new data show its seasonal flu vaccine is 26.6% more effective than a licensed standard-dose seasonal flu ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of selling combination vaccines. The shot’s efficacy was 27% higher ...